Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants

Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovi...

Descripción completa

Detalles Bibliográficos
Autores principales: Belik, Milja, Jalkanen, Pinja, Lundberg, Rickard, Reinholm, Arttu, Laine, Larissa, Väisänen, Elina, Skön, Marika, Tähtinen, Paula A., Ivaska, Lauri, Pakkanen, Sari H., Häkkinen, Hanni K., Ortamo, Eeva, Pasternack, Arja, Ritvos, Mikael A., Naves, Rauno A., Miettinen, Simo, Sironen, Tarja, Vapalahti, Olli, Ritvos, Olli, Österlund, Pamela, Kantele, Anu, Lempainen, Johanna, Kakkola, Laura, Kolehmainen, Pekka, Julkunen, Ilkka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072399/
https://www.ncbi.nlm.nih.gov/pubmed/35513437
http://dx.doi.org/10.1038/s41467-022-30162-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072399/
https://www.ncbi.nlm.nih.gov/pubmed/35513437
http://dx.doi.org/10.1038/s41467-022-30162-5

Ejemplares similares